Recomendaciones para el diagnóstico y manejo farmacológico en pacientes pediátricos con infección por SARS-CoV-2 (COVID-19)

Azurmendi, Daniela Pavez; Muñoz, Claudio González; Ortiz, Fernando Bernal; Pérez, Regina; Ávila, Mirta Acuña; Chacón, Ruth Rosales; Torres, José Perillán; Santibáñez, Paulina Quijarro; Goncalves, Crhistian Scheu; Fuenzalida, Luz María; Godoy, Jorge Pérez; Arancibia, José Miguel; Impellizzeri, Paula; Claude, María Eugenia Pinto

doi:10.4067/s0716-10182020000600625

Cited by 1 publication

(7 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Las dosis de tratamiento se deben indicar apenas se sospeche que existe una complicación tromboembólica (1,3) .…”

Section: Anticoagulaciónunclassified

“…Tanto instituciones internacionales como chilenas no recomiendan el uso de hidroxicloroquina de regla en los pacientes que cursan con Covid-19, salvo ensayos clínicos con criterios estandarizados (1,5) .…”

Section: Cloroquina/ Hidroxicloroquinaunclassified

“…Es necesario contar con más estudios de efectividad y seguridad, sobre todo clínicos aleatorizados para recomendarla como una alternativa válida contra Covid-19 (1,10) .…”

Section: Ivermectinaunclassified

“…Sin resultados conocidos en cuanto a la disminución de la mortalidad. Está aprobado para su uso como medicamento de emergencia por la FDA y el Ministerio de Sanidad de España (1,3,17) . Hasta un 5% de los pacientes hospitalizados podría presentar reacciones adversas (anemia, disminución de la filtración glomerular, leucopenia, falla respiratoria, pirexia, hiperglicemia y aumento niveles creatinina plasmática) (17) .…”

Section: Remdesivirunclassified

“…Corticoides (1,5) Inicialmente el uso de corticoides debía estar restringido a pacientes con SDRA severo, shock séptico y en descompensación de patologías de base, como asma y enfermedad pulmonar obstructiva crónica (EPOC).…”

unclassified

See 4 more Smart Citations

Tratamiento Covid-19

2021

Rev. Hosp. Clín. Univ. Chile (En línea)

View full text Add to dashboard Cite

The main treatment for patients with severe Covid-19 is to maintain adequate ventilatory support and monitor the possible progression of the disease. Therapeutic strategies such as High Flow Nasal Cannula, awake prone position, antithrombotic prophylaxis and the use of dexamethasone. There have improved the probability of not presenting complications and not requiring invasive mechanical ventilation. The use of convalescent plasma is still under investigation and is currently only recommended in clinical trials. Finding antivirals that allow treating the infection and clinically improving patients has led to mounting studies with different methodologies, and currently there are specific and limited indications for their routine use, as in the case of Remdesivir, which has been approved by the FDA as emergency treatment in severe cases. Immunomodulatory treatments are still under study. An example of this is Tocilizumab and Anakinra, which have shown promising results for the management of seriously ill patients. It should be noted that there are many therapies that are being tested and that every day the information about the results obtained is changing.

show abstract